Issue link: https://nebusinessmedia.uberflip.com/i/1547130
HARTFORDBUSINESS.COM | OCTOBER 19, 2026 3 Biz Briefs Tel: (860) 236-9998 | Fax: (860) 570-2493 Copyright 2020. All rights reserved. Postmaster: Please send address changes to: Hartford Business Journal P.O Box 330 Congers, NY 10920-9894 Subscriptions Annual subscriptions are $150.00. To subscribe, visit HartfordBusiness.com, email circulation@ hartfordbusiness.com, or call (845) 267-3008. Advertising For advertising information, please call (860) 236-9998. Please address all correspondence to: Hartford Business Journal, 100 Allyn Street, Suite 3, Hartford, CT 06103 Stay Connected For breaking and daily Greater Hartford business news go to: www.HartfordBusiness.com HBJ on Twitter: @HartfordBiz HBJ on Facebook: www.facebook.com/HartfordBiz HBJ on Linkedln:www.linkedin.com/company/the-Hart- ford-Business-Journal Daily e-newsletters: HBJ Today, CT Morning Blend: www.hartfordbusiness.com/enewsletters Hartford Business Journal (ISSN 1083-5245) is published bi-weekly, 27x per year — including two special issues in November and December — by New England Business Media, LLC, 100 Allyn Street, Suite 3, Hartford, CT 06103. Periodicals postage paid at Hartford, CT and at additional entry points. Tom Curtin | CEO, ext. 124, tcurtin@hartfordbusiness.com Editorial Greg Bordonaro | Editor, ext. 139 gbordonaro@hartfordbusiness.com Drew Larson | Web Editor, ext. 121 alarson@hartfordbusiness.com Beat: Energy Michael Puffer | Staff Writer, ext. 145 mpuffer@hartfordbusiness.com Beats: Real Estate, Economic Development, Banking & Finance David Krechevsky | Staff Writer, ext. 702 davidk@hartfordbusiness.com Beats: Health Care, Bioscience, State Government Harriet Jones | Staff Writer, ext. 145 hjones@hartfordbusiness.com Beats: Manufacturing, Cannabis, Professional Services Clarissa Garza | Staff Writer cgarza@hartfordbusiness.com Beats: Fairfield County, Real Estate, Economic Development Stephanie R. Meagher | Research Director Heide Martin | Research Assistant Steve Laschever | Photographer Business Tom Curtin | Publisher, ext. 124, tcurtin@hartfordbusiness.com Jessica M. Quinn | Associate Publisher, ext. 137 jquinn@hartfordbusiness.com Emily Paskind | Senior Accounts Manager, ext. 133, epaskind@hartfordbusiness.com Sadie Bride | Senior Accounts Manager, ext. 141, sbride@hartfordbusiness.com Destiny Cyr | Operations & Administrative Specialist, ext. 138 dcyr@hartfordbusiness.com Production Bartosz Zinowko | Production Director, ext. 147 bzinowko@hartfordbusiness.com Events Kathryn Pelletier | Director of Marketing and Events, ext. 136 kpelletier@hartfordbusiness.com New Haven's Bexorg wins federal award worth up to $28.3M A New Haven company that uses donated human brains to test potential treatments for neurological diseases has been awarded up to $28.3 million from the federal Advanced Research Projects Agency for Health. Bexorg will use the funding for a three-year project aimed at extending experiments from 24 hours to as long as two weeks. Its technology circulates fluid through the brain's blood vessels. Longer experiments would help researchers study repeated doses and sustained exposure to potential treatments for diseases including Parkinson's and Alzheimer's. Biohaven signs licensing deal worth up to $100M New Haven life sciences company Biohaven Ltd. has signed a licensing agreement with Japan's Ono Pharma- ceutical Co. that could provide $100 million in payments over the next year. Ono receives exclusive rights to develop and sell three of Biohaven's experimental autoimmune disease treatments in Japan, South Korea, Taiwan and Southeast Asia. Biohaven will receive $80 million upfront, another $20 million if an undis- closed milestone is met and royalties of approximately 20% on net sales. The lead drug, BHV-1300, is in Phase 3 trials for Graves' disease, which causes excessive thyroid hormone production. Biohaven retains rights elsewhere, including the United States, Europe and China. The agreement is Biohav- en's second international licensing deal in less than two months. Becton, Dickinson's $34M Canaan investment boosts syringe capacity more than 50% Medical device maker Becton, Dickinson and Co. has invested more than $34 million in its Canaan syringe plant over the past five years, increasing production capacity by more than 50%, the company said. The investment included three production lines that began operating last year, along with modernization and equipment upgrades. The plant employs about 560 people and produces approximately 2.6 billion syringes annually, making it the nation's largest syringe manu- facturing operation, according to the New Jersey-based company. The facility, which marked its 65th anniversary this month, opened in 1961 with eight employees and annual production of about 10 million syringes. The lobby of Becton, Dickinson and Co.'s syringe plant in Canaan. Contributed Photo Biohaven Chairman and CEO Dr. Vlad Coric. Contributed Photo A technician monitors data being harvested from experiments run on donated human brains on Bexorg's BrainEx platform. HBJ Photo | Harriet Jones PAM Health eyes UConn partnership as $33M Waterbury rehab hospital nears opening T he owner of a new $33 million rehabilitation hospital in Waterbury is discussing a potential partnership with UConn Health Waterbury Hospital as it prepares to begin accepting patients in November. Pennsylvania-based PAM Health says the talks could lead to Water- bury Hospital taking an ownership stake in the 55,000-square-foot facility at 351 Harpers Ferry Road. The hospitals could also collabo- rate and share services without an ownership agreement. The organizations originally planned to co-own the project, but Waterbury Hospital withdrew in 2024 amid financial problems at its former owner, Prospect Medical Holdings. Its subsequent acquisi- tion by the UConn Health Commu- nity Network opened the door to renewed discussions, said PAM Health CEO Anthony F. Misitano. The new hospital will provide intensive rehabilitation and ongoing medical care for patients recovering from strokes, serious injuries, surgery and other condi- tions. Hospital leaders say the region lacks sufficient inpatient rehabilitation capacity, sometimes forcing patients to remain in acute- care hospitals or travel elsewhere. The opening marks PAM Health's Connecticut debut, and the company says it is interested in further expansion in the state. PAM Health CEO Anthony F. Misitano. HBJ Photo | Michael Puffer Continued on next page